Prelude Capital Management’s COSCIENS Biopharma Inc. Common Stock CSCI Stock Holding History

Prelude Capital Management’s Portfolio CSCI Stock Details CSCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-107	Closed	-$22K	–	1772
2017 Q3	$22K	Buy	107 +97	+970%	+$17.9K	﹤0.01%	1301
2017 Q2	$1K	Buy	+10	New	+$1.58K	﹤0.01%	1556
2017 Q1	–	Sell	-4	Closed	-$1K	–	1824
2016 Q4	$1K	Sell	4 -13	-76%	-$4.84K	﹤0.01%	1502
2016 Q3	$6K	Buy	+17	New	+$5.96K	﹤0.01%	1480
2016 Q1	–	Sell	-4	Closed	-$2K	–	1566
2015 Q4	$2K	Buy	+4	New	+$2.51K	﹤0.01%	1404

Other funds holding CSCI

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

TSS

Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Prelude Capital Management's CSCI Position: Q4 2017 in Review

Prelude Capital Management sold out of COSCIENS Biopharma Inc. Common Stock (CSCI) in Q4 2017, closing a stake of 107 shares — an estimated $22K sold.

Prelude Capital Management first reported a position in CSCI in Q4 2015 and held it in 5 quarters. The position peaked at $22K in Q3 2017. 15 funds tracked by Wall St. Rank hold CSCI as of Q4 2017.

Prelude Capital Management reported no remaining COSCIENS Biopharma Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
Prelude Capital Management sold 107 COSCIENS Biopharma Inc. Common Stock shares in Q4 2017, an estimated $22K.
Prelude Capital Management first reported a position in COSCIENS Biopharma Inc. Common Stock in Q4 2015 and held it in 5 quarters.
Prelude Capital Management's COSCIENS Biopharma Inc. Common Stock position peaked at $22K in Q3 2017.
15 funds tracked by Wall St. Rank held COSCIENS Biopharma Inc. Common Stock as of Q4 2017.

Based on Prelude Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.